The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
Open accessAbstract
Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer. These patients are at a high risk of VTE recurrence and bleeding during anticoagulant therapy. The International Initiative on Thrombosis and Cancer is an independent academic working group aimed at establishing a global consensus for the treatment and prophylaxis of VTE in patients with cancer. The International Initiative on Thrombosis and Cancer last updated its evidence-based clinical practice guidelines in 2016 with a free, web-based mobile phone application, which was subsequently endorsed by the International Society on Thrombosis and Haemostasis. The 2019 International Initiative on Thrombosis and Cancer clinical practice guidelines, which are based on a systematic review of the literature published up to December, 2018, are presented along with a Grading of Recommendations Assessment Development and Evaluation scale methods, with the support of the French National Cancer Institute. These guidelines were reviewed by an expanded international advisory committee and endorsed by the International Society on Thrombosis and Haemostasis. Results from head-to-head clinical trials that compared direct oral anticoagulant with low-molecular-weight heparin are also summarised, along with new evidence for the treatment and prophylaxis of VTE in patients with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Self-citationOral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Self-citationBüller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Development and validation of a predictive model for chemotherapy-associated thrombosis
Khorana, A. A., Kuderer, N. M., Culakova, E., Lyman, G. H., & Francis, C. W. (2008) · Blood · doi:10.1182/blood-2007-10-116327 · Cited by 2,217
Self-citationEdoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869
Going from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy
KHORANA, A. A., FRANCIS, C. W., CULAKOVA, E., KUDERER, N. M., & LYMAN, G. H. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02374.x · Cited by 1,670
Self-citationEdoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Raskob, G. E., van Es, N., Verhamme, P., Carrier, M., Di Nisio, M., Garcia, D., Grosso, M. A., Kakkar, A. K., Kovacs, M. J., Mercuri, M. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1711948 · Cited by 1,633
Self-citation
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Wanhainen, A., Van Herzeele, I., Bastos Goncalves, F., Bellmunt Montoya, S., Berard, X., Boyle, J. R., D’Oria, M., Prendes, C. F., Karkos, C. D., Kazimierczak, A., et al. (2024) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2023.11.002 · Cited by 1,207
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Agnelli, G., Becattini, C., Meyer, G., Muñoz, A., Huisman, M. V., Connors, J. M., Cohen, A., Bauersachs, R., Brenner, B., Torbicki, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915103 · Cited by 1,067
Self-citationLyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003442 · Cited by 893
Self-citationKhan, F., Tritschler, T., Kahn, S. R., & Rodger, M. A. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32658-1 · Cited by 753
Metadata
- Authors
- Farge, D., Frere, C., Connors, J. M., Ay, C., Khorana, A. A., Munoz, A., Brenner, B., Kakkar, A., Rafii, H., Solymoss, S., Brilhante, D., Monreal, M., Bounameaux, H., Pabinger, I., Douketis, J., Ageno, W., Ajauro, F., Al-Aboudi, K. R., Alcindor, T., Andre, T., Angchaisuksiri, P., Antic, D., Arcelus, J. I., Assenat, E., Bauer, K. A., Bazarbachii, A., Benzidia, I., Beyer-Westendorf, J., Bitsadze, V., Blickstein, D., Blostein, M., Bogalho, I., Bournet, B., Casais, P., Carpentier, A. F., Cesarman-Maus, G., Chakbrabartty, J., Clemente, H., Connault, J., Doucet, L., Durant, C., Emmerich, J., Falanga, A., Feistritzer, C., Font, C., Francis, C., Gallardo, E., Gary, T., Gris, J.-C., Guillermo, C., Hij, A., Hull, R. D., IKezoe, T., Jara-Palomares, L., Key, N. S., Khrizroeva, J., Koolian, M., Langer, F., Le Hello, C., Lecumberri, R., Lee, L. H., Liebman, H., Lopes Dos Santos, L., Machado, D. H., Madelaine, I., Makatsariya, A., Mandala, M., Marayevas, A., Marjanovic, Z., Marosi, C., Martin, E., Meillon, L., Messas, E., Moreira, A., Demir, A. M., Ndour, A., Nguessan, M., Otero-Candelera, R., Pachon Olmos, V., Pais, A., Posch, F., Preusser, M., Riess, H., Righini, M., Rothschild, C., Roussin, A., Rueda-Camino, J. A., Ruiz-Artacho, P., Saseedharan, S., Shamseddine, A., Soff, G., Stricker, H., Tagalakis, V., Taher, A., Toussaint, T., Trujillo-Santos, J., Villiers, S., Wong, R., & Yamada, N.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 20
- Issue
- 10
- Pages
- e566-e581
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2972019042
- Cited by
- 651
- References
- 81
- FWCI
- 72.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. https://app.cochat.ai/papers/10.1016/s1470-2045(19)30336-5
- The paper
- Farge, D., Frere, C., Connors, J. M., Ay, C., Khorana, A. A., Munoz, A., Brenner, B., Kakkar, A., Rafii, H., Solymoss, S., Brilhante, D., Monreal, M., Bounameaux, H., Pabinger, I., Douketis, J., Ageno, W., Ajauro, F., Al-Aboudi, K. R., Alcindor, T., . . . Yamada, N. (2019). 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(19)30336-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.